top of page


Using digital tools to empower and improve the lives of patients with pancreatic cancer


Our Mission

Improving quality of life of advanced pancreatic cancer patients through an AI-guided multimodal intervention, combining pain and cachexia management, nutrition, and physical activity.

RELEVIUM empowers patients and assists them in living a less strenuous life while they are forced to endure the difficulties of pancreatic cancer.

Why Pancreatic Cancer Matters

Difficult to diagnose

Pancreatic cancer has one of the lowest survival rates among other cancers because it is difficult to diagnose early.


It is often diagnosed in later stages of the disease, once it has already metastasized.

Unresponsive tumor

The tumors from pancreatic cancer don't respond as well to commonly used cancer therapies as other less harmful types of cancer.

Serious comorbidities

Some of the comorbidities that exist as a result of pancreatic cancer are pain, emaciation, and jaundice, among others.

Our Objectives

  • Introducing an AI-guided multimodal intervention for patients with advanced pancreatic cancer 

  • Implement cutting-edge remote monitoring technologies for the intervention: multi-sensor smartwatch, remote ultrasound patch, combined an AI-driven platform for maximum QoL 

  • Enhance evidence on symptom progression for personalized care plans and to create new care pathways

  • Evaluate the efficacy of personalized care plans on the quality of life of patients

  • Investigate secondary outcomes: cost-effectiveness, health equity, and stress reduction for patients and their families

  • Facilitate patient-doctor communication, enabling patients to self-manage their disease


Improving the outcomes in palliative care for advanced pancreatic cancer through wearable technology and AI


Raise awareness about PDAC and create new health pathways for patients in the EU


RELEVIUM brings together an interdisciplinary team of experts and partners such as universities, research centers and SMEs


Currently conducting research about its project  through randomized clinical trials, feasibility, and data collection study



Funding for this project has been provided by the European Union's Horizon Europe research and innovation programme under grant agreement No 101057821. The material presented and views expressed here are the responsibility of the author(s)only.

The EU Commission takes no responsibility for any use made of the information set out.


bottom of page